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TISSUE  REGENERATION  
Better  growth    factor  binding  aids  tissue  repair  
Enhancing  the  binding  of  growth  factors  to  heparan  sulphate  proteoglycans  in  the  extracellular  matrix  and  on  cell  
surfaces  improves  wound  healing  and  bone  regeneration  in  mice.  
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By  interacting  with  cells  and  the  surrounding  extracellular  matrix  (ECM),  growth  factors  regulate  cellular  processes  such  as  
proliferation,  differentiation  and  wound  healing.  Hence,  these  signalling  proteins  hold  great  promise  in  regenerative  medicine  
applications,  in  particular  for  tissue  repair.  However,  despite  some  clinical  success,  suboptimal  efficacy  and  limitations  in  the  
delivery  and  slow  clearance  of  growth  factors  have  led  to  treatment  regimens  that  administer  them  in  supraphysiological  
doses  and  that  often  lead  to  unwanted  adverse  effects.  Strategies  for  addressing  some  of  these  issues  involve  improving  the  
binding  affinity  of  growth  factors  to  ECM  molecules,  for  greater  stability  and  control  over  growth  factor  release,  bioavailability  
and  spatiotemporal  cellular  signalling,  and  boosting  the  signalling  strength  of  growth  factors  by  modifying  their  affinity  for  cell-­  
surface  proteins  rather  than  those  in  the  ECM.  Proteoglycans  —  a  class  of  complex  glycoproteins  containing  
glycosaminoglycan  (GAG)  chains  attached  to  core  proteins  —  are  ideally  suited  as  binding  targets  for  such  engineered  
growth  factors.  This  is  because  proteoglycans  are  ubiquitously  expressed  in  the  ECM  and  at  the  cell  surface  of  almost  all  
mammalian  tissues,  and  because  they  exert  diverse  biological  functions  via  the  selective  binding  of  the  GAG  chains  to  
growth  factors  and  other  proteins1.  
Growth  factors  can  be  modified2  to  display  higher  affinity  for  the  transmembrane-­protein  family  of  heparan  sulphate  
proteoglycans  (HSPGs).  HSPGs  control  the  activity  of  multiple  HS-­binding  growth  factors,  including  those  involved  in  tissue-­  
repair  processes  such  as  fibroblast  growth  factors,  vascular  endothelial  growth  factors  (VEGFs)  and  platelet-­derived  growth  
factors3  (PDGFs).  Reporting  in  Nature  Biomedical  Engineering,  Mikaël  Martino  and  colleagues  now  show  that  growth  factors  
modified  for  improved  control  of  their  release  from  ECM-­based  carriers  and  for  improved  binding  to  cell-­  surface  
proteoglycans  enhance  the  efficacy  of  tissue  repair  in  mice4.  
Martino  and  co-­authors  added  additional  HS  -­  binding  sites  to  VEGF-­A  and  PDGF-­BB  by  using  a  peptide  derived  from  the  
heparin  binding  region  of  the  alpha  subunit  of  laminin.  The  peptide,  which  is  commonly  known  as  AG73,  binds  to  cell-­  surface  
HSPGs  of  the  syndecan  family  via  their  HS  side-­  chains.  For  VEGF-­A165,  which  lacks  the  natural  HS-­binding  site  found  in  
the  longer  VEGF  variants,  the  addition  of  the  AG73  peptide  yielded  a  construct  (VEGF-­A-­SB;;  with  SB  meaning  syndecan  
binding)  with  high  affinity  binding  to  HS  (2–4-­fold  higher  affinity  for  syndecans  than  VEGF-­A165).  By  contrast,  for  PDGF-­BB,  
which  contains  a  natural  HS  -­binding  domain,  the  authors  fused  the  AG73  peptide  as  an  additional  SB  site,  resulting  in  a  
construct  (PDGF-­BB-­SB)  with  4–6-­fold  higher  affinity  for  syndecans.  Although  these  effects  were  consistent  with  
expectations  from  previous  studies3,  signalling  assays  indicated  that  VEGF-­A-­SB  and  PDGF-­BB-­SB  elicited  altered  kinetics  
in,  respectively,  endothelial  cells  and  in  mesenchymal  stem  cells.  Whilst  wild-­type  VEGF-­A165  and  PDGF-­BB  led  to  ‘burst’  
signalling  (that  is,  elevated  but  short-­lived;;  Fig.  1a),  VEGF-­A-­SB  and  PDGF-­BB-­SB  displayed  ‘tonic’  signalling  (that  is,  
sustained  and  of  lower  intensity;;  Fig  1b).  In  addition,  VEGF-­A-­SB  and  PDGF-­BB-­SB  were  retained  for  longer  periods  on  cell  
surfaces,  owing  to  their  expected  binding  to  cell-­  surface  syndecans  (and  possibly  to  other  HSPGs).  Also,  they  triggered  
significantly  lower  desensitization  of  their  cognate  receptors  (measured  as  internalisation  and  degradation)  than  their  wild-­
type  counterparts.  These  altered  kinetics  suggest  that  the  engineered  growth  factors  might  be  advantageous  for  tissue  repair.  
Moreover,  the  authors  added  an  additional  fibrin-­binding  site  based  on  residues  1–8  from  the  alpha-­2  plasmin-­inhibitor  (α2PI1–
8),  with  an  intervening  matrix-­metalloprotease  cleavage  site.  These  constructs,  termed  α2PI1–8-­M-­PDGF-­BB-­SB  and  α2PI1–8-­
VEGF-­A-­SB,  could  bind  to  the  ECM  and  to  HS.  Cell-­based  assays  showed  that  these  constructs  had  further  increased  
potency,  with  α2PI1–8-­M-­PDGF-­BB-­SB  showing  higher  and  more  sustained  activity  in  promoting  the  proliferation  and  colony  
formation  of  mesenchymal  stem  cells.  Likewise,  α2PI1–8-­M-­VEGF-­A-­SB  displayed  higher  and  sustained  activity  in  endothelial  
cells,  promoting  their  proliferation  as  well  as  angiogenesis.  
To  test  the  ability  of  α2PI1–8-­M-­PDGF-­BB-­SB  and  α2PI1–8-­VEGF-­A-­SB  to  repair  tissue  in  vivo,  Martino  and  co-­authors  
delivered  the  constructs  in  a  fibrin  matrix  at  doses  lower  than  those  required  for  the  wild-­type  variants  in  the  context  of  bone  
repair.  α2PI1–8-­M-­PDGF-­BB-­SB  was  delivered  within  a  fibrin  matrix  placed  around  critical-­size  calvarial  defects  in  mice.  Whilst  
wild-­type  PDGF-­BB  did  not  significantly  increase  bone  regeneration,  α2PI1–8-­M-­PDGF-­BB-­SB  and  α2PI1–8-­VEGF-­A-­SB  led  to  
significant  increases  in  bone  coverage  and  volume.  In  the  context  of  wound  healing,  the  authors  delivered  VEGF  proteins  to  
full-­thickness  skin  wounds  in  diabetic  mice  and  quantified  granulation  tissue  (new  connective  tissue  and  blood  vessels)  as  
well  as  the  extent  of  wound  closure  evidenced  by  re-­epithelialization.  The  wild-­type  variants  VEGF-­A121  and  VEGF-­A165,  
and  also  α2PI1–8-­M-­VEGF-­A165,  did  not  promote  healing,  yet  α2PI1–8-­M-­VEGF-­A-­SB  led  to  enhanced  granulation  and  wound  
closure.  Furthermore,  angiogenesis  (key  in  sustaining  newly-­formed  granulation  tissue)  was  most  strongly  promoted  by  
α2PI1–8-­M-­VEGF-­A-­SB.  
A  key  criterion  for  evaluating  the  potential  clinical  value  of  such  engineered  growth  factors  is  the  relative  risk  of  them  causing  
adverse  effects  (PDGF-­BB  increases  cancer  risk,  and  VEGF-­A  increases  vascular  permeability).  Martino  and  colleagues  
show  that  α2PI1–8-­M-­PDGF-­BB-­SB  did  not  lead  to  the  accelerated  tumour  growth  observed  in  mice  treated  with  PDGF-­BB  or  
M-­PDGF-­BB,  and  that  in  classic  in  vivo  vascular-­permeability  assays  in  mice  α2PI1–8-­M-­VEGF-­A-­SB  induced  markedly  lower  
levels  of  vascular  leakage  when  compared  with  α2PI1–8-­M-­VEGF-­A121  and  α2PI1–8-­M-­VEGF-­A165.  These  results  suggest  
that  the  engineered  constructs  are  safer  than  the  wild-­type  growth  factors  and  than  the  constructs  only  incorporating  SB.  
Hence,  the  ‘multi-­site’  strategy  of  adding  additional  ECM  and  proteoglycan  binding  domains  into  growth  factors  is  a  promising  
strategy  for  enhancing  tissue  repair.  
Additional  work  is  however  needed  to  fully  elucidate  the  mechanisms  of  action  of  the  engineered  growth  factor  constructs.  In  
particular,  the  AG73  peptide  is  likely  to  bind  generically  to  HS  on  HSPGs  present  in  the  ECM  and  on  the  cell  surface,  rather  
than  just  to  syndecans,  and  the  extent  and  location  of  binding  is  likely  to  be  variable  in  different  tissues,  depending  on  the  HS  
binding  site  used.  Further  investigation  of  the  tonic  signalling  is  warranted  to  ensure  that  unwanted  longer-­term  side-­effects  
are  not  induced  in  multiple  tissues.  Increased  understanding  of  such  factors  will  underpin  the  development  of  engineered  
growth  factors  with  multiple  optimized  properties,  including  ECM  and  cell-­surface  affinities  and  localization,  and  growth  factor  
release,  stability  and  signalling  activity.  This  could  result  in  reduced  dosages,  adverse  effects  and  costs.  Furthermore,  this  
strategy  may  provide  opportunities  to  tune  many  more  tissue-­repair  signalling  molecules.  Similar  strategies  for  enhancing  the  
affinity  of  growth  factors  for  their  receptors  include  the  addition  of  the  heparin-­binding  domain  of  the  epidermal  growth  factor,  
of  binding  domains  for  matrix  molecules  such  as  collagen,  fibronectin,  fibrin  and  matrix  metalloproteinases,  and  of  plasmin  
cleavage  sites;;  these  modifications  altered  the  binding  and  residence  time  of  the  growth  factors  in  tissues,  and  enabled  their  
controlled  release  from  biomaterial  scaffolds3,5.  
Typically,  tissue-­repair  approaches  have  focused  on  biomaterial  scaffolds  presenting  GAGs  as  growth  factor-­binding  
partners6.  The  most  widely  explored  GAG  in  these  applications  is  heparin,  because  of  its  commercial  availability,  and  
because  it  often  improves  performance  when  presented  alone  or  with  exogenous  growth  factors6–8.  Owing  to  heparin’s  
frequent  suboptimal  growth  factor  signalling  and  adverse  effects  as  an  anticoagulant,  the  development  of  natural9,10  and  
chemoenzymatic11  GAG  saccharide  libraries  may  help  discover  potent  HS  structures  that  can  replace  heparin  in  these  
approaches.  Also,  non-­mammalian  polysaccharides  such  as  chitosan  and  alginate  are  abundant,  biocompatible  and  readily  
available,  and  have  been  used  as  biomaterials  alone  or  in  hybrid  scaffolds  after  chemical  modification  to  promote  
endogenous  growth  factor  interactions12.  The  incorporation  of  proteoglycans  into  tissue-­repair  strategies  hasn’t  been  widely  
explored,  most  likely  because  of  their  low  abundance  and  high  cost,  and  because  of  challenges  in  their  expression  with  
functional  GAGs7.  
Gene-­delivery  approaches  using  biomaterial  scaffolds  have  led  to  wound  repair  by  simultaneously  inducing  proteoglycan  and  
growth  factor  expression13,  and  gene-­editing  techniques  for  engineering  libraries  of  proteoglycans  with  designer  GAGs  are  
starting  to  be  tested14.  The  potential  for  synergy  of  genetic  interventions  and  the  administration  of  engineered  proteoglycan-­
binding  growth  factors  could  further  facilitate  the  control  of  tissue-­repair  processes.  
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Fig.  1  |  Engineering  growth  factors  for  tonic  signalling.  a,  Many  native  growth  factors  contain  heparan  sulphate  (HS)  binding  sites  
that  enable  them  to  bind  to  HS  proteoglycans  (such  as  perlecan,  agrin  and  collagen  type  XVIII)  in  the  extracellular  matrix  and  on  the  cell  
surface  (through  syndecans,  glypicans  and  betaglycans).  Native  growth  factors  are  rapidly  released  from  the  extracellular  matrix,  and  when  
presented  to  proteoglycan  receptors  on  the  cell  surface  elicit  rapid  ‘burst’  signalling.  b,  Growth  factors  engineered  to  contain  an  additional  
HS-­binding  peptide  that  also  binds  to  syndecans  (denoted  as  SB,  for  syndecan  binding),  a  fibrin-­scaffold-­binding  motif  (α2PI1–8-­M)  and  a  
matrix-­metalloproteinase  cleavage  site  (M)  are  slowly  released  from  fibrin-­based  scaffolds,  resulting  in  sustained  low-­intensity  signalling  
(tonic  signalling)  and  enhanced  tissue  repair.  
[Note  for  the  art  editor:  All  panels  are  original.  See  attached  file  for  a  vector  version  of  the  figure.  Please  replace  
‘Native  GF  signalling’  with  ‘Burst  signalling’,  and  ‘Designer  GF  tonic  signalling’  with  ‘Tonic  signalling’.  ‘Betaglycan’  
should  read  ‘Betaglycans’.  ‘Syndecans’  and  ‘Glypicans’  should  also  be  in  their  plural  form.  Please  also  add  hyphens  
in  ‘Extracellular-­matrix  binding’,  ‘Fibrin-­scaffold  binding’,  ‘Cell-­surface  binding’.  ‘GF  receptor’  should  read  ‘Growth-­
factor  receptor’.  ‘Other’  should  be  capitalized.  Please  remove  ‘HSPGs’  and  the  four  lines  of  text  below  the  top  
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